HCV-infected patients need access now to new direct-acting antiviral agents to avert liver- related deaths
Summary No abstract available. Countries: Australia Read the Full Report
-
-
Forecasting the disease burden of chronic hepatitis C virus in Poland
Summary Background and Aims Chronic hepatitis C virus infection is prevalent among 200,000 individuals in Poland; however, few are aware of their condition (30,000 diagnosed) and even fewer are treated (2490 in 2014). This analysis projected future disease burden and developed two treatment scenarios to control or eliminate hepatitis C virus-related disease in Poland. Methods […]
-
Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2
Summary The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, […]
-
The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2
Summary Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was […]
-
Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2
Summary Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, […]
-
Estimates on HCV disease burden worldwide – filling the gaps
Summary Hepatitis C is caused by infection with the hepatitis C virus (HCV) and represents a major global health burden. Persistent HCV infection can lead to progressive liver disease with the development of liver cirrhosis and hepatocellular carcinoma, possibly accounting for up to 0.5 million deaths every year. Treatment of HCV infection is undergoing a […]
-
Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand
Summary Background Chronic hepatitis C is an important cause of liver failure, liver cancer and liver-related deaths in New Zealand. Although these complications can be prevented by HCV eradication, current treatment uptake is <1% per annum. We describe the burden of HCV infection and estimate the effect of four different treatment strategies to reduce HCV-related […]
-
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Summary Objective Recently, new highly effective direct-acting antivirals (DAAs) against hepatitis C virus (HCV) were introduced. Whether these will alleviate the anticipated increase of liver disease burden in Sweden is unknown, partly because high costs may restrict the use. The objectives were to model the HCV epidemic in Sweden, the burden of disease, and the […]
-
Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end‐stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue
Summary No abstract available. Countries: Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, Egypt, England, France, Germany, Portugal, Spain, Sweden, Switzerland, Turkey Read the Full Report
-
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality
Summary Background The societal, clinical and economic burden imposed by the complications of chronic hepatitis C virus (HCV) infection – including cirrhosis and hepatocellular carcinoma (HCC) – is expected to increase over the coming decades. However, new therapies may improve sustained virological response (SVR) rates and shorten treatment duration. This study aimed to estimate the […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic